World pharmaceutical market

For the moment, then, it is not appropriate to talk of a world pharmaceutical market as such, as there are fragmented domestic markets corresponding to each country s geographical boundaries, each characterized by its own system of price regulation and intervention. 

The EU is currently composed of 27 member states and a total population of 480 million (compared with 250 million in the USA and 125 million in Japan, the other two world pharmaceutical markets). The total European pharmaceutical market value stands at 70 billion, representing almost 33 per cent of world sales (the US and Japanese figures are 31 per cent and 21 per cent respectively). Annual expenditure on European pharmaceutical R D stands at about 17 billion. 

One should consider that plant-derived steroids alone account for about 15% ( 22 billion) of the 150 billion world pharmaceuticals market and that the annual market for taxol exceeded 1 billion in the year 2000. The antineoplastic agents vinblastine and vincristine have sales amounting to 100 million per year the market for psyllium seed products amounts to some 300 million annually and nicotine and scopolamine patches now have combined sales of more than 1 billion per year. It is obvious that natural products continue to play important economic as well as therapeutic roles in modem medicine. 

World Pharmaceutical Markets Canada Espicom Business Intelligence Chichester, UK, May, 1999 9-48. 

World Pharmaceutical Markets United Kingdom Espicom Business Intelligence Chichester, UK, Eeb 1999 17-70. World Pharmaceutical Markets Germany Espicom Business Intelligence Chichester, UK, Eeb 1999. 

The world pharmaceutical market is buoyant and grew in 2000 by US 21 billion to a total of 309-6 billion (Figure 10.1). However, the... 

World Pharmaceutical Markets. England Espicom Business Intelligence. A profiling service, which focuses on the demographic, economic, and political factors which infiuence health-care markets in individual countries. Individual reports cover one country, and are updated periodically as new information becomes available. This is arguably the best source of health data for the third world and smaller markets. Most of this information is unavailable elsewhere. 

Fig. 1.2 The US constituted half of the world pharmaceutical market in 2003 (US billions) [5].

The world antibiotic market for 1989, estimated at 12.3 billion dollars (20), was the second biggest pharmaceutical category accounting for approximately 9% of the total world pharmaceutical market. Cardiovascular agents (qv) were first. In 1988 antibiotic production in the United States was 13.1 x 10 kg compared to central nervous system depressants and stimulants, 22.3 x 10 kg, gastrointestinal agents and therapeutic nutrients, 45.2 x 10 kg, and vitamins, 17.5 x 10 kg (21). The leading pharmaceutical companies for the manufacture and sales of antibiotics in 1989 are listed in Table 2 (2). 

Nearly three decades passed since the time when the first representatives of the fluoroquinolone family of antibacterials, such as norfloxacin, pefloxacin, ciprofloxacin and ofloxacin had appeared in the world pharmaceutical market (Scheme 1). 

BMl Espicom (2013) World Pharmaceutical Markets Fact Book 2013, Espicom Business IntelUgence Ltd. 

---